Aproximadamente 87% em três semanas: o que a estratégia de reservas pré-lançamento de uma empresa de biotecnologia demonstra.
InSitu Biologics, a company developing a non-opioid post-surgical pain medication, built a pipeline of non-binding investment reservations before its Regulation A+ offering was qualified by the SEC. Those reservations carried an incentive to lock in the initial issue price. When the offering went live, approximately 87% of the reservations converted into actual investments within três semanas. We worked with the company on the raise. We own stock in InSitu Biologics, and I personally invested in the company, so we have a disclosed interest in its outcome.
Escrito e revisado por
Resposta rápida
The reservations were non-binding and offered a lock-in of the initial issue price. They were sourced mainly from the founder speaking on biotech industry panels rather than from paid advertising. An approximate pipeline of US $ 1 milhões a US $ 1.6 milhões was already in place before advertising began. When the Regulation A+ offering went live, approximately 87% of those reservations converted within três semanas. This is a single historical case. We cannot verify whether the conversion rate is a record because we do not have competitor data.
The Pre-Launch Reservation Mechanism
Ahead of SEC qualification, the founder and primary investor invited prospective investors to make non-binding reservations for the upcoming Regulation A+ offering. The incentive attached to those reservations was a lock-in of the initial issue price. The commitments were explicitly non-binding.
How the Pipeline Was Built
The primary source of the reservations was the founder speaking on multiple panels in the biotech industry. During those appearances, the upcoming Regulation A+ was discussed, and attendees were invited to reserve. The resulting pre-committed pipeline was approximately $ 1 $ 1.6 milhões. That interest existed before any paid advertising for the Regulation A+ began.
Conversion at Launch
When the offering went live, approximately 87% of the reservations converted into investments within três semanas. The pre-existing pipeline was in place before broader marketing started. We believe the conversion rate may be a record, but we cannot prove it. We do not have the data on other offerings that would be required for a verified comparison.
Limits of the Case
This is a single historical observation from one biotech company. The approximate 87% conversion and the approximate $ 1.6 milhões pipeline are specific to this raise. They are not presented as typical, expected, or repeatable results for other issuers. Our ownership of stock and my personal investment in InSitu Biologics are disclosed so readers can evaluate the account with that context in mind.
If you have questions about pre-launch reservation strategies or Regulation A+ offerings, email [email protected].
Sobre o autor
Rod Turner
Fundador e CEO da Manhattan Street Capital
Rod Turner é o fundador e CEO da Manhattan Street Capital, onde construiu a plataforma que empresas em fase de crescimento utilizam para realizar captações de recursos online, de acordo com a Regulação A+.
Anteriormente, ele ajudou a construir a Symantec/Norton, a Ashton Tate, a MicroPort e a Knowledge Adventure, além de ter criado a empresa de capital de risco Irvine Ventures, investindo em empresas como Bloom, Amyris, Ask Jeeves e eASIC.
Os comentários nesta página refletem as observações de Rod sobre o que tende a funcionar no marketing online para captação de recursos. Não se trata de aconselhamento jurídico, contábil ou de investimento.
Perguntas frequentes
What made the InSitu Biologics reservations non-binding?
The founder invited prospective investors to make reservations ahead of SEC qualification. Those reservations were non-binding and carried an incentive to lock in the initial issue price.
How were the reservations primarily sourced?
They came mainly from the founder speaking on multiple biotech industry panels where the upcoming Regulation A+ was discussed, and attendees were invited to reserve.
How large was the pre-committed pipeline before advertising began?
The pipeline was approximately US $ 1 milhões a US $ 1.6 milhões and was already in place before paid advertising for the Regulation A+ started.
What conversion rate was observed after the offering went live?
Approximately 87% of the reservations converted into actual investments within três semanas of the offering going live.
Can the approximate 87% conversion be treated as a verified record?
No. We believe it may be a record, but we cannot prove it because we do not have competitor data for comparison.
Does Manhattan Street Capital have an interest in InSitu Biologics?
Yes. We own stock in the company, and I personally invested in it. That interest is disclosed.
A Manhattan Street Capital não é um escritório de advocacia, serviço de avaliação, subscritora, corretora de valores mobiliários ou plataforma de financiamento coletivo (crowdfunding) do Título III, e não se envolve em nenhuma atividade que exija tal registro. A Manhattan Street Capital não oferece consultoria de investimentos e não estrutura transações. Não interprete nenhum comentário da equipe da Manhattan Street Capital como substituto para aconselhamento de profissionais qualificados nessas áreas. Quando Rod Turner comenta, baseia-se em suas observações sobre o que funciona e o que não funciona, do ponto de vista de marketing, em ofertas online; ele não diz aos leitores o que fazer, apenas o que tem maior probabilidade de ser comercializado online com custo-benefício. Todas as decisões sobre os termos de qualquer oferta são tomadas pelas empresas que a realizam.
